Status:
UNKNOWN
Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
Lead Sponsor:
Radboud University Medical Center
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Brief Summary
Infections in critically ill patients are a major healthcare problem and an important source of morbidity and mortality. Since critically ill patients often have altered pharmacokinetics (PK) compared...
Eligibility Criteria
Inclusion
- The patient is admitted to the ICU or ED;
- The patient is at least 18 years of age on the day of inclusion;
- Is managed with a central venous catheter or arterial line;
- Is treated with amikacin and/or cefuroxime as standard care.
Exclusion
- 1\. Has previously participated in this study.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04470973
Start Date
July 15 2020
End Date
December 15 2023
Last Update
September 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc intensive care
Nijmegen, Netherlands